PrimeRFP SCOUT · Federal Contract Recompete Brief

36C25026N0080F-18 AMYVID radiopharmaceutical 10 MCI — Eli Lilly and Company

Eli Lilly and Company holds $282K across 4 federal awards, concentrated at Department of Veterans Affairs (VA). The prior award was single-bid — competitive dynamics may favor a challenge. Recompete timing centers on the Oct 5, 2026 PoP end — agencies typically plan 12–18 months ahead.

250-Network Contract Office 10 (36C250)
Awarding office
Eli Lilly and Company
Recipient
Oct 5, 2026
PoP end
$230K
Obligated
$230K
Potential
325412
NAICS
6505
PSC
1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Eli Lilly and Company — $90

Contract facts

Federal
Contract number36C25026N0080
Also listed as36C250-26-N-0080
Also listed as36F79725D0226-36C25026N0080
Agency250-Network Contract Office 10 (36C250)
Awarding office250-Network Contract Office 10 (36C250)
Awarding agencyDepartment of Veterans Affairs (VA)
Funding agencyDepartment of Veterans Affairs (VA)
IncumbentEli Lilly and Company
CAGE75602
UEIUHHVNTY54K68
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV36F79725D0226
Place of performanceINDIANAPOLIS IN
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startOct 6, 2025
PoP end (current)Oct 5, 2026
Obligated$230K
Current value$230K
Potential value$230K

AMYVID RADIOPHARMACEUTICAL 10 MCI FLORBETAPIR F-18 INJ,SOLN is a federal award for 250-Network Contract Office 10 (36C250) held by Eli Lilly and Company. Estimated value $230K ($230K obligated). Current period of performance ends Oct 5, 2026. Last award drew 1 bidder. Place of performance: INDIANAPOLIS IN.

AMYVID RADIOPHARMACEUTICAL 10 MCI FLORBETAPIR F-18 INJ,SOLN

Recompete timing

Public
Expiring in 45 days

Current PoP ends Oct 5, 2026 (45 days remaining). Agencies typically plan 12–18 months ahead — at 1.5 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Eli Lilly and Company$282K obligated across 4 awards (firm-wide, all agencies).

Sole agency: Department of Veterans Affairs (VA)
Department of Veterans Affairs (VA)$282K · 100% of firm total
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 36C25026N0080?

36C25026N0080 (F-18 AMYVID radiopharmaceutical 10 MCI) is a 250-Network Contract Office 10 (36C250) award with a potential value of $230K, currently held by Eli Lilly and Company. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C250-26-N-0080?

36C250-26-N-0080 is the dashed form of PIID 36C25026N0080 (F-18 AMYVID radiopharmaceutical 10 MCI), held by Eli Lilly and Company. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C25026N0080?

250-Network Contract Office 10 (36C250) awarded 36C25026N0080 to Eli Lilly and Company (potential $230K).

Who is the incumbent on 36C25026N0080?

Eli Lilly and Company is the incumbent with $282K across 4 related awards in SCOUT’s public footprint. The current period of performance ends Oct 5, 2026.

When does Eli Lilly and Company’s 36C25026N0080 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 5, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/36C25026N0080